Vanderbilt University Medical Center: International Study Supports Dupilumab for Treatment of Moderate-to-Severe Asthma in Children
December 09, 2021
December 09, 2021
NASHVILLE, Tennessee, Dec. 9 (TNSJou) -- Vanderbilt University Medical Center issued the following news:
By Leigh MacMillan
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.
The findings of the international multicenter Liberty Asthm . . .
By Leigh MacMillan
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.
The findings of the international multicenter Liberty Asthm . . .